The publications with and about APST reflect the multifaceted research projects and care topics of our network. Current issues in the care of people with rare neurological diseases are covered as well as innovative therapies and digital medicine. All publications are available for download as PDF files. If you have any questions, please write to us at: [email protected]
March 2023
In this study, neurofilament light chain (NfL) was examined in SOD1-ALS before and during treatment with Tofersen. The data show a significant decrease in NfL after Tofersen treatment. The response of NfL to Tofersen treatment supports the assumption that Tofersen influences the disease course of ALS.
March 2023
In a study with 14 ALS outpatient clinics, the significance of the serum neurofilament light chain (sNfL) in ALS was investigated in a broad spectrum of disease courses in relation to the course and duration of the disease.
August 2022
Publication about the recording of the ALS Functional Scale (ALSFRS-R) via web portal or ALS app. Data from 620 people with ALS who digitally recorded the ALS Functional Scale were evaluated. The result was impressive: 9.6 times per year, those affected completed the ALS Functional Scale digitally.
Juni 2022
The results of our study on the benefit of therapeutic movement trainers (digitTHERA) in amyotrophic lateral sclerosis (ALS). In a period from February 2019 to January 2021, the data of 144 people with ALS who use an exercise trainer were collected and evaluated at 10 ALS centres in Germany.
Mai 2021
Publication of our observational study of a therapy with nusinersen in adults with 5q-spinal muscular atrophy (5q-SMA). In the period from July 2019 to September 2020, the data of 151 people with 5q-SMA were collected and analyzed at 9 SMA treatment centers in Germany.
March 2021
The FU Berlin, the WWU Münster and the Einstein Center Digital Future have researched our digital supply and research platform. The results are available in a publication for an international readership.
April 2020
Scientific investigation of symptomatic treatment with medications in amyotrophic lateral sclerosis (ALS). Data from 2.392 people with ALS who participated in our digital-assisted medication management were analyzed.
September 2019
In the article, data from the Ambulanzpartner Network on the treatment of spasticity with nabiximols in amyotrophic lateral sclerosis (ALS) are published. The study shows differential use of nabiximols in ALS.
November 2018
We surveyed 256 people with ALS in the period 07/2014 to 08/2017 about their remedy care. The analysis of the data shows that the satisfaction of ALS patients with physiotherapy, occupational therapy and speech therapy is predominantly high.
August 2018
The supply of assistive devices at 12 leading German ALS centers was evaluated over a period of 4 years. The data of 1.494 ALS patients with 11.364 supplies of aids via the care platform Ambulanzpartner were analyzed.
Januar 2016
NeuroTransmitter sees itself as a discussion forum and leading professional medium for neurologists, neurologists and psychiatrists in Germany. With the article, we would like to achieve comprehensive information and a sound understanding for APST in the target group.
August 2015
A first scientific evaluation of aggregated care data from the Ambulanzpartner network. The data of the digitized care processes provide for the first time an independent direct comparison of services of the health insurance companies in the field of medical aids for people with ALS.
June 2013
Tbe journal “Klinische Neurophysiologie” is aimed at neurophysiologists, neurologists, neurosurgeons and neurologists in clinic and practice. In the article, Ambulanzpartner is described in detail using the example of care for people with amyotrophic lateral sclerosis (ALS).
